These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9109178)

  • 1. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients.
    Lane HY; Hu OY; Jann MW; Deng HC; Lin HN; Chang WH
    Psychiatry Res; 1997 Mar; 69(2-3):105-11. PubMed ID: 9109178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients.
    Jann MW; Chang WH; Davis CM; Chen TY; Deng HC; Lung FW; Ereshefsky L; Saklad SR; Richards AL
    Psychiatry Res; 1989 Oct; 30(1):45-52. PubMed ID: 2594870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
    Ulrich S; Neuhof S; Braun V; Meyer FP
    Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients.
    Lin KM; Poland RE; Nuccio I; Matsuda K; Hathuc N; Su TP; Fu P
    Am J Psychiatry; 1989 Oct; 146(10):1307-11. PubMed ID: 2782476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
    Furukori H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
    Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
    J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dextromethorphan metabolic phenotyping in an Iranian population.
    Afshar M; Rouini M; Ala S
    Eur J Clin Pharmacol; 2005 Feb; 60(12):849-54. PubMed ID: 15657780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
    Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
    Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
    Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP
    Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
    Hu OY; Tang HS; Lane HY; Chang WH; Hu TM
    J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
    Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
    Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YW; Jann MW
    Schizophr Res; 1993 Mar; 9(1):35-40. PubMed ID: 8461270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
    Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
    Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects.
    Scherer J; Tatsch K; Schwarz J; Oertel WH; Konjarczyk M; Albus M
    Acta Psychiatr Scand; 1994 Oct; 90(4):266-8. PubMed ID: 7831996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes.
    Krakowski M; Czobor P; Volavka J
    Psychiatry Res; 1997 Jun; 71(1):19-26. PubMed ID: 9247978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.
    Chen R; Wang H; Shi J; Hu P
    Int J Clin Pharmacol Ther; 2016 May; 54(5):330-6. PubMed ID: 26902503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
    McEvoy JP; Stiller RL; Farr R
    J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.